Super Seton announces the closing of a series A share issue. The investors are two experienced Healthtech entrepreneurs, Bart Bergstein & Michiel Manuel, who will join the advisory board of the company. SuperSeton is an innovative knotless seton for use in perianal fistula and has been developed by the Amsterdam UMC (Amsterdam University Medical Centre), MediShield and NLC | the Healthtech Venture Builder. The product is expected to be launched in 2018, following CE marking. For more information contact Ernst Elhorst, CEO.